These materials are from an analysis funded in part by the National Institutes of Health. We are sharing these on the Harvard Dataverse in compliance with the Data Sharing and Management Plan associat
BackgroundThe initiation of antiretroviral treatment based on a 2-drug regimen (2DR) with dolutegravir plus lamivudine has demonstrated non-inferior efficacy than dolutegravir-based three-drug regimen